Poirier, John T.

Keap1 loss promotes Kras-driven lung cancer and results in dependence on glutaminolysis

Romero, R., Sayin, V. I., Davidson, S. M., Bauer, M. R., Singh, S. X., LeBoeuf, S. E., Karakousi, T. R., Ellis, D. C., Bhutkar, A., Sánchez-Rivera, F. J., et al. (2017) · Nature Medicine

Genomics, phytochemicals, and oxidative stressLung Cancer Treatments and Mutations

Cited by 652

RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer

Niederst, M. J., Sequist, L. V., Poirier, J. T., Mermel, C. H., Lockerman, E. L., Garcia, A. R., Katayama, R., Costa, C., Ross, K. N., Moran, T., et al. (2015) · Nature Communications

Lung Cancer Treatments and MutationsLung Cancer Research Studies

Cited by 647

NK cell–mediated cytotoxicity contributes to tumor control by a cytostatic drug combination

Ruscetti, M., Leibold, J., Bott, M. J., Fennell, M., Kulick, A., Salgado, N. R., Chen, C.-C., Ho, Y.-J., Sanchez-Rivera, F. J., Feucht, J., et al. (2018) · Science

Immune Cell Function and InteractionTelomeres, Telomerase, and Senescence

Cited by 415

A combinatorial strategy for treating KRAS-mutant lung cancer

Manchado, E., Weissmueller, S., Morris, J. P., Chen, C.-C., Wullenkord, R., Lujambio, A., de Stanchina, E., Poirier, J. T., Gainor, J. F., Corcoran, R. B., et al. (2016) · Nature

Lung Cancer Treatments and MutationsProtein Kinase Regulation and GTPase Signaling

Cited by 403

ULK1 inhibition overcomes compromised antigen presentation and restores antitumor immunity in LKB1-mutant lung cancer

Deng, J., Thennavan, A., Dolgalev, I., Chen, T., Li, J., Marzio, A., Poirier, J. T., Peng, D. H., Bulatovic, M., Mukhopadhyay, S., et al. (2021) · Nature Cancer

Cancer Immunotherapy and BiomarkersAutophagy in Disease and Therapy

Cited by 140